Related MeSH Hierarchy (6)
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Carcinoma » Adenocarcinoma » Carcinoma, Islet Cell
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Digestive System Neoplasms » Pancreatic Neoplasms » Carcinoma, Islet Cell
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Endocrine Gland Neoplasms » Pancreatic Neoplasms » Carcinoma, Islet Cell
Diseases [C] » Digestive System Diseases [C06] » Digestive System Neoplasms » Pancreatic Neoplasms » Carcinoma, Islet Cell
Diseases [C] » Digestive System Diseases [C06] » Pancreatic Diseases » Pancreatic Neoplasms » Carcinoma, Islet Cell
Diseases [C] » Endocrine System Diseases [C19] » Endocrine Gland Neoplasms » Pancreatic Neoplasms » Carcinoma, Islet Cell
Description
A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively. MeSH
Hierarchy View
Subtype Terms (4)
Gastrinoma
18 drugs (14 approved, 4 experimental)
Glucagonoma
14 drugs (11 approved, 3 experimental)
Somatostatinoma
16 drugs (12 approved, 4 experimental)
Vipoma
10 drugs (8 approved, 2 experimental)
Phase 3 Indicated Drugs (1)
Phase 2 Indicated Drugs (22)
Phase 1 Indicated Drugs (5)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (25)
Academic and Community Cancer Research United
Advanced Accelerator Applications
Eastern Cooperative Oncology Group
Grupo Espanol de Tumores Neuroendocrinos (GETNE)
National Cancer Institute, France
Organization Involved with Phase 1 Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
